Gelonghui, April 17 | Health Source (600380.SH) announced that recently, the company's innovative drug product TG-1000 capsules for use in a multi-center phase III clinical trial (referred to as this study) with no complications in acute influenza A and B infections aged 12 and above (referred to as this study) reached the end of the main study. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules.
健康元(600380.SH)：TG-1000胶囊Ⅲ期临床试验达到主要终点
Health Source (600380.SH): TG-1000 capsule phase III clinical trial reached the main end
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.